Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2005 | 1 |
2007 | 1 |
2024 | 0 |
Search Results
2 results
Results by year
Filters applied: . Clear all
Page 1
ABO blood group barrier in allogeneic bone marrow transplantation revisited.
Biol Blood Marrow Transplant. 2005 Dec;11(12):1006-13. doi: 10.1016/j.bbmt.2005.07.015.
Biol Blood Marrow Transplant. 2005.
PMID: 16338623
Free article.
A total of 3103 patients with early-stage leukemia who underwent transplantation between 1990 and 1998 with bone marrow from an HLA-identical sibling and who were reported to the Center for International Blood and Marrow Transplant Research were studied. ...There was no ev …
A total of 3103 patients with early-stage leukemia who underwent transplantation between 1990 and 1998 with bone marrow from an HLA-i …
Impact of imatinib therapy on the use of allogeneic haematopoietic progenitor cell transplantation for the treatment of chronic myeloid leukaemia.
Giralt SA, Arora M, Goldman JM, Lee SJ, Maziarz RT, McCarthy PL, Sobocinski KA, Horowitz MM; Chronic Leukemia Working Committee, Center for International Blood and Marrow Transplant Research.
Giralt SA, et al.
Br J Haematol. 2007 Jun;137(5):461-7. doi: 10.1111/j.1365-2141.2007.06582.x. Epub 2007 Apr 24.
Br J Haematol. 2007.
PMID: 17459051
Free article.
The discovery and approval of imatinib drastically changed the therapeutic algorithm for chronic myeloid leukaemia (CML). Imatinib is now considered the therapy of choice for patients with newly diagnosed CML, including those previously considered candidates for all …
The discovery and approval of imatinib drastically changed the therapeutic algorithm for chronic myeloid leukaemia (CML). Imat …
Item in Clipboard
Cite
Cite